A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer
出版年份 2017 全文链接
标题
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung Cancer
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 109, Issue 11, Pages -
出版商
Oxford University Press (OUP)
发表日期
2017-03-17
DOI
10.1093/jnci/djx063
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer
- (2016) M. Chatterjee et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overspending driven by oversized single dose vials of cancer drugs
- (2016) Peter B Bach et al. BMJ-British Medical Journal
- Overspending driven by oversized single dose vials of cancer drugs
- (2016) Peter B Bach et al. BMJ-British Medical Journal
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Receipt of Chemotherapy Among Medicare Patients With Cancer by Type of Supplemental Insurance
- (2015) Joan L. Warren et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
- (2015) Gregory A. Masters et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Necitumumab in Metastatic Squamous Cell Lung Cancer
- (2015) Daniel A. Goldstein et al. JAMA Oncology
- Indication-Specific Pricing for Cancer Drugs
- (2014) Peter B. Bach JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non-Small Cell Lung Cancer
- (2013) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
- (2013) Sean D. Sullivan et al. VALUE IN HEALTH
- Referral and Treatment Patterns Among Patients With Stages III and IV Non–Small-Cell Lung Cancer
- (2013) Bernardo H.L. Goulart et al. Journal of Oncology Practice
- Approval Summary: Pemetrexed in the Initial Treatment of Advanced/Metastatic Non-Small Cell Lung Cancer
- (2009) M. H. Cohen et al. ONCOLOGIST
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search